Recon: GSK pays $500M upfront to Hengrui for rights to several drugs; PE firms offer $3B to buy Bavarian Nordic
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.In Focus: US
- New analysis predicts sprawling effects of proposed NIH budget cuts (STAT)
- Trump targets supervised consumption of drugs and harm reduction in executive order (STAT)
- Did a drug prevent this man’s ALS? (STAT)
- FDA 'Expert Panels' Raise Concerns of Evading Regulations, Ethics (MedPage Today)
- US Health, Tech Officials to Launch Data-Sharing Plan (Bloomberg)
- FDA launches probe into new Elevidys death as Sarepta, Roche stress gene therapy not at fault (Fierce Pharma)
- US health chief Kennedy targets vaccine injury compensation program (Reuters)
- EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say (Reuters)
- European regulators endorse Lilly’s Alzheimer’s treatment for certain patients (STAT)
- Europe moves to reject embattled Duchenne muscular dystrophy gene therapy (STAT)
- Shanghai biotech VelaVigo snags $60M after landing two licensing deals (Endpoints)
- Indian drugmaker Torrent Pharma's quarterly profit jumps on strong demand (Reuters)
- NICE To Consult On UK Late-Stage Healthtech Assessments (MedTech Insight)
- GSK pays $500M upfront for rights to series of Hengrui drugs (STAT)
- Updated: Private equity firms eye $3B deal for vaccine maker Bavarian Nordic (Endpoints)
- Roche to Test Whether New Drug Can Prevent Alzheimer’s (Bloomberg)
- MapLight gets $372.5M for CNS pipeline in year's third-largest private round (Endpoints)
- Recognify’s schizophrenia drug fails mid-stage test, backer atai’s stock dips (Endpoints)
- Celcuity posts Phase 3 win in breast cancer, setting up challenge to Novartis and Roche (Endpoints)
- Novo Nordisk faces 'show me' moment to boost Wegovy growth after US copycat ban (Reuters)
- Celcuity's triple drug combo tops AstraZeneca's treatment in breast cancer trial (Reuters)
- Edwards loses longtime TAVR leader Larry Wood (MedTech Dive)
- EU/US Trade Deal Raises Questions For Medtech (MedTech Insight)
- Roche Diagnostics Growth Flattens As China Reforms Bite; Bets On US Manufacturing, CGM For Growth (MedTech Insight)
- Award-Winning Lioness Implant Addresses ‘Silent Emergency’ Of Preterm Birth (MedTech Insight)
- Boston Scientific Raises Outlook … Again: Headwinds Offset By EP And Watchman (MedTech Insight)
- Voluntary sustainable packaging goals are on the way out, Gartner says (Food Dive)
- FDA looks to answer the question: What makes food ultra processed? (Food Dive)
- Researchers sequence complex parts of human genome, expanding the future of precision medicine (STAT)
- Hospitals boost their profit expectations for 2025 as health insurers stumble (STAT)
- The lessons New York still has not learned from the Covid vaccine rollout (STAT)
- UnitedHealth investors may seek roadmap on costs as Hemsley takes center stage (Reuters)
- Medical group urges Kennedy not to fire US care task force (Reuters)
- Oyez, Oyez, Oyez! Effective August 1, DEA Will Have No Administrative Law Judges (FDA Law Blog)
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
